{"DataElement":{"publicId":"2749868","version":"1","preferredName":"Antiphospholipid Syndrome Laboratory Procedure Type","preferredDefinition":"A description of the antiphospholipid syndrome laboratory procedure.","longName":"AP_SYN_LAB_TYP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2749866","version":"1","preferredName":"Antiphospholipid Syndrome Laboratory Procedure","preferredDefinition":"A syndrome associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses, marked by the presence of antibodies directed against phospholipids._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","longName":"AP_SYN_LAB","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2675009","version":"1","preferredName":"Antiphospholipid Syndrome","preferredDefinition":"A syndrome associated with a variety of diseases, notably systemic lupus erythematosus and other connective tissue diseases, thrombopenia, and arterial or venous thromboses, marked by the  presence of antibodies directed against phospholipids.","longName":"C61283","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antiphospholipid Syndrome","conceptCode":"C61283","definition":"A disorder caused by the presence of autoantibodies directed against phospholipids, causing a hypercoaguable state, which may result in blood clots, stroke, heart attack, and in women, significant pregnancy-related complications, including miscarriage and still birth. The syndrome is often associated with other autoimmune disorders, most commonly lupus erythematosus, and infections, including syphilis and Lyme disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"38B33F67-55F0-3ECE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-27","modifiedBy":"SBREXT","dateModified":"2008-02-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2486250","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"15A9DA1A-D89C-6C6C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-07","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-06-07","modifiedBy":"ONEDATA","dateModified":"2006-06-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D495EF5-C6C0-4794-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2749000","version":"1","preferredName":"Autoimmune Disease Laboratory Procedure Type","preferredDefinition":"A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents.  It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis). -- 2003_Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Type; a subdivision of a particular kind of thing.","longName":"AI_DZ_LAB_TYP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"19","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"ACA positive","valueDescription":"Centromere Antibody","ValueMeaning":{"publicId":"2749001","version":"1","preferredName":"Centromere Antibody","longName":"2749001","preferredDefinition":"The nonstaining primary constriction of a chromosome which is the point of attachment of the spindle fiber; provides the mechanism of chromosome movement during cell division; the centromere divides the chromosome into two arms, and its position is constant for a specific chromosome: near one end (acrocentric), near the center (metacentric), or between (submetacentric).: (AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Centromere","conceptCode":"C13198","definition":"The nonstaining primary constriction of a chromosome which is the point of attachment of the spindle fiber; provides the mechanism of chromosome movement during cell division; the centromere divides the chromosome into two arms, and its position is constant for a specific chromosome: near one end (acrocentric), near the center (metacentric), or between (submetacentric).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1DAA23-ACCE-1748-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1DAA23-ACE7-1748-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"C3","valueDescription":"Complement Component 3","ValueMeaning":{"publicId":"2749013","version":"1","preferredName":"Complement Component 3","longName":"2749013","preferredDefinition":"Complement Component 3, encoded by the C3 gene plays a central role in the activation of complement system. Its activation is required for both classical and alternative complement activation pathways. People with C3 deficiency are susceptible to bacteria infection. (From LocusLink)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complement C3","conceptCode":"C21527","definition":"Complement C3 (1663 aa, ~187 kDa) is encoded by the human C3 gene. This protein plays a role in complement-mediated immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1E9A9F-57D2-5293-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1E9A9F-57EB-5293-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"Anticardiolipin IgM","valueDescription":"Anticardiolipin IgM Antibody","ValueMeaning":{"publicId":"2749014","version":"1","preferredName":"Anticardiolipin IgM Antibody","longName":"2749014","preferredDefinition":"Anticardiolipin antibodies react with proteins (e.g. beta2 glycoprotein I, prothrombin, or annexin V) bound to anionic phospholipids, such as cardiolipin and phosphatidylserine. Different immunoglobulin subclasses and isotypes are associated with anticardiolipin antibodies, including IgM.  Some anticardiolipin antibodies prolong phospholipid dependent clotting assays, exhibiting properties of lupus anticoagulants.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anticardiolipin IgM Antibody","conceptCode":"C70619","definition":"An IgM autoantibody directed against cardiolipin. It is associated with hemolytic anemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1E9A9F-57F7-5293-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1E9A9F-5810-5293-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"Anticardiolipin IgG","valueDescription":"Anticardiolipin IgG Antibody","ValueMeaning":{"publicId":"2749015","version":"1","preferredName":"Anticardiolipin IgG Antibody","longName":"2749015","preferredDefinition":"An IgG autoantibody directed against cardiolipin. It is associated with blood clotting complications.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anticardiolipin IgG Antibody","conceptCode":"C70990","definition":"An IgG autoantibody directed against cardiolipin. It is associated with thrombosis, spontaneous abortion, and complications during labor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1E9A9F-581C-5293-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1E9A9F-5835-5293-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"Anti Pr3","valueDescription":"ELISA Proteinase 3 Antibody","ValueMeaning":{"publicId":"2749016","version":"1","preferredName":"ELISA Proteinase 3 Antibody","longName":"2749016","preferredDefinition":"A highly sensitive technique for detecting and measuring antigens or antibodies in a solution; the solution is run over a surface to which immobilized antibodies specific to the substance have been attatched, and if the substance is present, it will bind to the antibody layer, and its presence is verified and visualized with an application of antibodies that have been tagged in some way. (BioTech Life Science Dictionary): Encoded by human PRTN3 Gene (Peptidase S1 Family), 256-aa 29-kD Proteinase 3 precursor is coordinately expressed with and packed in neutrophilic azurophil granules with ELA2 and AZU during myeloid development. An antibiotic neutral serine protease, PRTN3 appears to degrade elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV by preferential cleavage at Ala-X and Val-X bonds. (from LocusLink, Swiss-Prot, OMIM, and NCI): (AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ELISA","conceptCode":"C16553","definition":"A highly sensitive technique for detecting and measuring antigens or antibodies in a solution; the solution is run over a surface to which immobilized antibodies specific to the substance have been attached, and if the substance is present, it will bind to the antibody layer, and its presence is verified and visualized with an application of antibodies that have been tagged in some way. (BioTech Life Science Dictionary)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloblastin","conceptCode":"C17548","definition":"Myeloblastin (256 aa, ~28 kDa) is encoded by the human PRTN3 gene. This protein is involved in the proteolysis of extracellular matrix proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1E9A9F-5841-5293-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1E9A9F-585A-5293-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"Anti MPO","valueDescription":"ELISA Myeloperoxidase Antibody","ValueMeaning":{"publicId":"2749017","version":"1","preferredName":"ELISA Myeloperoxidase Antibody","longName":"2749017","preferredDefinition":"A highly sensitive technique for detecting and measuring antigens or antibodies in a solution; the solution is run over a surface to which immobilized antibodies specific to the substance have been attatched, and if the substance is present, it will bind to the antibody layer, and its presence is verified and visualized with an application of antibodies that have been tagged in some way. (BioTech Life Science Dictionary): Myeloperoxidase (745 aa, ~84 kDa) is encoded by the human MPO gene. This protein is involved in innate host defense by facilitating the oxygen-dependent mechanism of apoptosis.: (AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"ELISA","conceptCode":"C16553","definition":"A highly sensitive technique for detecting and measuring antigens or antibodies in a solution; the solution is run over a surface to which immobilized antibodies specific to the substance have been attached, and if the substance is present, it will bind to the antibody layer, and its presence is verified and visualized with an application of antibodies that have been tagged in some way. (BioTech Life Science Dictionary)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloperoxidase","conceptCode":"C71145","definition":"Myeloperoxidase (745 aa, ~84 kDa) is encoded by the human MPO gene. This protein is involved in the regulation of the innate host defense through the production of hypohalous acids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1E9A9F-5866-5293-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1E9A9F-587F-5293-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"ANA","valueDescription":"Antinuclear Antibody","ValueMeaning":{"publicId":"2749018","version":"1","preferredName":"Antinuclear Antibody","longName":"2749018","preferredDefinition":"An autoimmune antibody that is directed against structures within the nucleus of the cell.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antinuclear Antibody","conceptCode":"C70547","definition":"An autoimmune antibody that is directed against structures within the nucleus of the cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1E9A9F-588B-5293-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1E9A9F-58A4-5293-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"C4","valueDescription":"Complement Component-4","ValueMeaning":{"publicId":"2749021","version":"1","preferredName":"Complement Component-4","longName":"2749021","preferredDefinition":"Complement component-4 (1744 aa, ~193 kDa) is part of the complement cascade, which mediates the innate immune response to infection. The full length protein is a precursor that can is secreted as a trimeric molecule containing an alpha, beta and gamma chain. When the complement cascade is initiated, the protein is cleaved. This proteolysis releases both the alpha chain, C4 anaphylatoxin, which stimulates inflammation, and a dimer of the beta and gamma chains, which mediates the interaction between the antigen-antibody complex and other complement components.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complement Component-4","conceptCode":"C70618","definition":"Complement component-4 (1744 aa, ~193 kDa) is part of the complement cascade, which mediates the innate immune response to infection. The full length protein is a precursor that is secreted as a trimeric molecule containing an alpha, beta and gamma chain. When the complement cascade is initiated, the protein is cleaved. This proteolysis releases both the alpha chain, C4 anaphylatoxin, which stimulates inflammation, and a dimer of the beta and gamma chains, which mediates the interaction between the antigen-antibody complex and other complement components.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1ED1DC-AE0D-5F72-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1ED1DC-AE26-5F72-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"Other","valueDescription":"Antibody Other","ValueMeaning":{"publicId":"2749022","version":"1","preferredName":"Antibody Other","longName":"2749022","preferredDefinition":"(AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.: Not otherwise specified.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1ED1DC-AE35-5F72-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1ED1DC-AE4E-5F72-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"Lupus anticoagulant","valueDescription":"Lupus Anticoagulant Antibody","ValueMeaning":{"publicId":"2749023","version":"1","preferredName":"Lupus Anticoagulant Antibody","longName":"2749023","preferredDefinition":"Antibodies directed against plasma proteins (such as beta-2-glycoprotein I, prothrombin, or annexin V) bound to anionic phospholipids. The anticoagulant blocks in vitro assembly of the prothrombinase complex, resulting in prolongation of in vitro clotting assays such as the activated partial thromboplastin time, the russell viper venom time, and others. Paradoxical to these changes which suggest impaired coagulation, patients with the lupus anticoagulant have an increase in thrombotic events.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lupus Anticoagulant Antibody","conceptCode":"C70620","definition":"Antibodies directed against plasma proteins (such as beta-2-glycoprotein I, prothrombin, or annexin V) bound to anionic phospholipids. The anticoagulant blocks in vitro assembly of the prothrombinase complex, resulting in prolongation of in vitro clotting assays such as the activated partial thromboplastin time, the Russell viper venom time, and others. Paradoxical to these changes which suggest impaired coagulation, patients with the lupus anticoagulant have an increase in thrombotic events.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1ED1DC-AE5A-5F72-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1ED1DC-AE73-5F72-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"Lab lupus inhibitor","valueDescription":"Lab Lupus Inhibitor","ValueMeaning":{"publicId":"2749024","version":"1","preferredName":"Lab Lupus Inhibitor","longName":"2749024","preferredDefinition":"Laboratory test to determine whether a lupus anticoagulant is present in the subject. Presence of a lupus inhibitor is most often detected by prolongation of the activated partial thromboplastin time. Presence of a lupus anticoagulant may actually increase risk for blood clots, and may indicate presence of systemic lupus. See definition of lupus anticoagulant for more details.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lab Lupus Inhibitor Test","conceptCode":"C70648","definition":"Laboratory test to determine whether a lupus anticoagulant is present in the subject. Presence of a lupus inhibitor is most often detected by prolongation of the activated partial thromboplastin time. Presence of a lupus anticoagulant may actually increase risk for blood clots, and may indicate presence of systemic lupus. See definition of lupus anticoagulant for more details.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1ED1DC-AE7F-5F72-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1ED1DC-AE98-5F72-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"Hepatitis serology","valueDescription":"Hepatitis Serological","ValueMeaning":{"publicId":"2749025","version":"1","preferredName":"Hepatitis Serological","longName":"2749025","preferredDefinition":"Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.: Pertaining to the in vitro reactions and properties of immune sera, particularly, the concept refers to the use of such reactions to measure serum titers of antibody against infectious and non-infectious agents (serologic tests), to the clinical correlations of the antibody titer, and to the use of serologic reactions to detect antigens.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hepatitis","conceptCode":"C3095","definition":"Inflammation of the liver; usually from a viral infection, but sometimes from toxic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Serological","conceptCode":"C41264","definition":"Pertaining to the in vitro reactions and properties of immune sera, particularly, the concept refers to the use of such reactions to measure serum titers of antibody against infectious and non-infectious agents (serologic tests), to the clinical correlations of the antibody titer, and to the use of serologic reactions to detect antigens.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1ED1DC-AEA4-5F72-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D1ED1DC-AEBD-5F72-E044-0003BA3F9857","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ALEYR","dateModified":"2008-05-13","deletedIndicator":"No"},{"value":"Total complement","valueDescription":"Complement Hemolytic Activity Assay","ValueMeaning":{"publicId":"2749805","version":"1","preferredName":"Complement Hemolytic Activity Assay","longName":"2749805","preferredDefinition":"A screening assay for circulating complement proteins in which diluted serum samples are added to antibody-coated erythrocytes and the percentage of cell lysis is measured. The values are expressed in hemolytic complement units per milliliter (CH50), the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complement Hemolytic Activity Assay","conceptCode":"C70611","definition":"A screening assay for circulating complement proteins in which diluted serum samples are added to antibody-coated erythrocytes and the percentage of cell lysis is measured. The values are expressed in hemolytic complement units per milliliter (CH50), the dilution of serum required to lyse 50 percent of the erythrocytes in the assay.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D44EEFB-2FA2-721C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D44EEFB-2FBB-721C-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"ALEYR","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"Scl 70 positive","valueDescription":"Topoisomerase I Antibody","ValueMeaning":{"publicId":"2749806","version":"1","preferredName":"Topoisomerase I Antibody","longName":"2749806","preferredDefinition":"Encoded by human TOP1 Gene (TOPI Family), 765-aa 90.7-kD monomeric DNA Topoisomerase I catalyzes transient ATP-independent breaking/rejoining of DNA and controls DNA topology during transcription. DNA topoisomerases I and II relax negative and positive supercoils; TOP1 breaks single DNA strands, TOP2 breaks duplex DNA. Specifically inhibited by the antitumor plant alkaloid CPT, when TOP1 breaks the DNA backbone bond it forms a protein-DNA link (a tyrosyl oxygen joins to a DNA strand end phosphorus). (from LocusLink, Swiss-Prot, OMIM, and NCI): (AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DNA Topoisomerase 1","conceptCode":"C16516","definition":"DNA topoisomerase 1 (765 aa, ~91 kDa) is encoded by the human TOP1 gene. This protein plays a role in the regulation of DNA topology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D44EEFB-2FC7-721C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D44EEFB-2FE0-721C-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"ALEYR","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"p-ANCA positive","valueDescription":"Unknown Laboratory Procedure Myeloperoxidase Antibody","ValueMeaning":{"publicId":"2749807","version":"1","preferredName":"Unknown Laboratory Procedure Myeloperoxidase Antibody","longName":"2749807","preferredDefinition":"Not known, not observed, not recorded, or refused.: A medical procedure that involves testing a sample of blood, urine, or other substance from the body. Tests can help determine a diagnosis, plan treatment, check to see if treatment is working, or monitor the disease over time.: Myeloperoxidase (745 aa, ~84 kDa) is encoded by the human MPO gene. This protein is involved in innate host defense by facilitating the oxygen-dependent mechanism of apoptosis.: (AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloperoxidase","conceptCode":"C71145","definition":"Myeloperoxidase (745 aa, ~84 kDa) is encoded by the human MPO gene. This protein is involved in the regulation of the innate host defense through the production of hypohalous acids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D44EEFB-2FEC-721C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D44EEFB-3005-721C-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"ALEYR","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"p-ANCA IFA","valueDescription":"Fluorescent Antibody Technique Myeloperoxidase Antibody","ValueMeaning":{"publicId":"2749809","version":"1","preferredName":"Fluorescent Antibody Technique Myeloperoxidase Antibody","longName":"2749809","preferredDefinition":"An immunological technique in which the antibodies are coupled with molecules which fluoresce under ultra violet (UV) light. This makes them particularly suitable for detection of specific antigens in tissues or on cells.: Myeloperoxidase (745 aa, ~84 kDa) is encoded by the human MPO gene. This protein is involved in innate host defense by facilitating the oxygen-dependent mechanism of apoptosis.: (AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorescent Antibody Procedure","conceptCode":"C17370","definition":"An immunological procedure in which the antibodies are coupled with molecules which fluoresce under ultra violet (UV) light. This makes them particularly suitable for detection of specific antigens in tissues or on cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloperoxidase","conceptCode":"C71145","definition":"Myeloperoxidase (745 aa, ~84 kDa) is encoded by the human MPO gene. This protein is involved in the regulation of the innate host defense through the production of hypohalous acids.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D44EEFB-3011-721C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D44EEFB-302A-721C-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"ALEYR","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"ds DNA","valueDescription":"Anti-DNA Antibody","ValueMeaning":{"publicId":"2749810","version":"1","preferredName":"Anti-DNA Antibody","longName":"2749810","preferredDefinition":"One of a number of antinuclear autoantibodies.  Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anti-DNA Antibody","conceptCode":"C1580","definition":"An antinuclear autoantibody directed against nuclear DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D44EEFB-3036-721C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D44EEFB-304F-721C-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"ALEYR","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"c-ANCA positive","valueDescription":"Unknown Laboratory Procedure Proteinase 3 Antibody","ValueMeaning":{"publicId":"2749811","version":"1","preferredName":"Unknown Laboratory Procedure Proteinase 3 Antibody","longName":"2749811","preferredDefinition":"Not known, not observed, not recorded, or refused.: A medical procedure that involves testing a sample of blood, urine, or other substance from the body. Tests can help determine a diagnosis, plan treatment, check to see if treatment is working, or monitor the disease over time.: Encoded by human PRTN3 Gene (Peptidase S1 Family), 256-aa 29-kD Proteinase 3 precursor is coordinately expressed with and packed in neutrophilic azurophil granules with ELA2 and AZU during myeloid development. An antibiotic neutral serine protease, PRTN3 appears to degrade elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV by preferential cleavage at Ala-X and Val-X bonds. (from LocusLink, Swiss-Prot, OMIM, and NCI): (AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloblastin","conceptCode":"C17548","definition":"Myeloblastin (256 aa, ~28 kDa) is encoded by the human PRTN3 gene. This protein is involved in the proteolysis of extracellular matrix proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D44EEFB-305B-721C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D44EEFB-3074-721C-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"ALEYR","dateModified":"2008-05-15","deletedIndicator":"No"},{"value":"c-ANCA IFA","valueDescription":"Fluorescent Antibody Technique Proteinase 3 Antibody","ValueMeaning":{"publicId":"2749812","version":"1","preferredName":"Fluorescent Antibody Technique Proteinase 3 Antibody","longName":"2749812","preferredDefinition":"An immunological technique in which the antibodies are coupled with molecules which fluoresce under ultra violet (UV) light. This makes them particularly suitable for detection of specific antigens in tissues or on cells.: Encoded by human PRTN3 Gene (Peptidase S1 Family), 256-aa 29-kD Proteinase 3 precursor is coordinately expressed with and packed in neutrophilic azurophil granules with ELA2 and AZU during myeloid development. An antibiotic neutral serine protease, PRTN3 appears to degrade elastin, fibronectin, laminin, vitronectin, and collagen types I, III, and IV by preferential cleavage at Ala-X and Val-X bonds. (from LocusLink, Swiss-Prot, OMIM, and NCI): (AN-tih-BOD-ee) A type of protein made by certain white blood cells in response to a foreign substance (antigen). Each antibody can bind to only a specific antigen. The purpose of this binding is to help destroy the antigen. Antibodies can work in several ways, depending on the nature of the antigen. Some antibodies destroy antigens directly. Others make it easier for white blood cells to destroy the antigen.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorescent Antibody Procedure","conceptCode":"C17370","definition":"An immunological procedure in which the antibodies are coupled with molecules which fluoresce under ultra violet (UV) light. This makes them particularly suitable for detection of specific antigens in tissues or on cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Myeloblastin","conceptCode":"C17548","definition":"Myeloblastin (256 aa, ~28 kDa) is encoded by the human PRTN3 gene. This protein is involved in the proteolysis of extracellular matrix proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Antibody","conceptCode":"C16295","definition":"A type of protein made by B lymphocytes in response to a foreign substance (antigen). Each antibody only binds to a specific antigen, helping to destroy the antigen directly or by assisting white blood cells to destroy the antigen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D44EEFB-3080-721C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4D44EEFB-3099-721C-E044-0003BA3F9857","beginDate":"2008-05-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"ALEYR","dateModified":"2008-05-15","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2748999","version":"1","preferredName":"Autoimmune Disease Laboratory Procedure Type","preferredDefinition":"A condition in which the body recognizes its own tissues as foreign and directs an immune response against them.:A medical procedure that involves testing a sample of blood, urine, or other substance from the body. Tests can help determine a diagnosis, plan treatment, check to see if treatment is working, or monitor the disease over time.:Type; a subdivision of a particular kind of thing.","longName":"C2889:C25294:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Autoimmune Disease","conceptCode":"C2889","definition":"A disorder resulting from loss of function or tissue destruction of an organ or multiple organs, arising from humoral or cellular immune responses of the individual to his own tissue constituents. It may be systemic (e.g., systemic lupus erythematosus), or organ specific, (e.g., thyroiditis).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1DAA23-ACA8-1748-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"ONEDATA","dateModified":"2008-05-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D1DAA23-ACB9-1748-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-13","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-13","modifiedBy":"SBR","dateModified":"2008-12-08","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"DefinedObservation:nameCode","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"For the antiphospholipid synd","type":"Preferred Question Text","description":"For the antiphospholipid syndrome, what was the laboratory procedure type?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2749868","type":"BRIDG Mapping Path","description":"PerformedClinicalResult >  PerformedObservation > DefinedObservation.nameCode WHERE DefinedObservation.nameCode = \"testing for antibody <name>\"  AND PerformedClinicalResult > AssessedResultRelationship > PerformedObservation [dx] > PerformedDiagnosis.value = \"antiphospholipid syndrome\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4D495EF5-C6DC-4794-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-15","endDate":null,"createdBy":"ALEYR","dateCreated":"2008-05-15","modifiedBy":"KUMMEROA","dateModified":"2021-04-28","changeDescription":". 2021-4-28 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}